The expansion of disease categories over the past four decades has been one of the quieter revolutions in medicine. Conditions that were once considered personality traits, life-stage challenges, or social problems have been re-classified as medical disorders with diagnostic criteria, treatment protocols, and pharmaceutical markets. Some of this expansion captured real human suffering that medicine had previously dismissed. Some of it medicalized normal human variation in ways that haven’t obviously made anyone better off. Sorting which is which is the work, and the conversation rarely happens carefully.
The DSM expansion as a case study
The Diagnostic and Statistical Manual of Mental Disorders, published by the American Psychiatric Association, has roughly tripled in length since DSM-II appeared in 1968. New categories appeared. Existing categories broadened their criteria. Some diagnoses that captured genuine, previously-overlooked suffering — including PTSD, formally added in 1980 — clearly belonged. Others have been more contested. Critics including Allen Frances, who chaired the DSM-IV task force, have publicly argued that the DSM-5 expansion in 2013 medicalized normal grief, ordinary worry, and age-appropriate behavior in children. The pharmaceutical industry funds significant portions of the research that defines diagnostic thresholds, and the relationship has been documented in detail in journals including BMJ and JAMA. None of this means specific diagnoses are illegitimate — it means the boundary between “disease” and “human experience” is partly negotiated, not purely discovered.
Costs that don’t appear in the diagnosis
Receiving a medical label changes things in ways that extend beyond treatment. It reshapes self-concept, sometimes helpfully — patients describe relief at finally having an explanation — and sometimes harmfully, as people internalize a chronic identity for what might have been a temporary state. It opens access to medications that work for some patients and harm others. It can shift attention from structural causes of distress (overwork, isolation, poverty, bad relationships) to individual biological ones, with treatments that don’t address the structural drivers. Diagnostic labels also have insurance, employment, and legal consequences. The benefits of labeling are often immediate and visible; the costs unfold over years and are harder to attribute.
The legitimate counterpoint
The case against medicalization can itself be overstated. Conditions that genuinely respond to treatment — major depression, severe anxiety, ADHD, bipolar disorder, schizophrenia — were under-diagnosed and under-treated for most of the twentieth century, particularly in women, minorities, and lower-income populations. The expansion of recognition saved real lives and reduced real suffering. Critics who treat all medicalization as overreach miss this. The honest position requires holding two things at once: recognition has corrected real historical neglect, and the same expansion has crossed into territory that probably shouldn’t be medical. Both claims have evidence. Neither cancels the other.
The takeaway
Whether labeling a condition as a disease helps or harms depends on what the label leads to — accurate self-understanding and effective treatment, or chronic identification with a category and treatments that don’t address what’s actually driving the distress. The reflexive answers, in either direction, are too crude. Better questions are situational: does this label, for this person, in this context, lead to better outcomes than the alternative? That conversation is harder, and worth having.
Leave a Reply